← All trials
NCT07015268
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2025
- Primary completion
- Nov 30, 2027
- Completion date
- Nov 30, 2027
- First posted
- Jun 11, 2025
- Last posted
- Jun 15, 2025
- Enrollment
- 288
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kissei PharmaceuticalsLead sponsor
- Kissei PharmaceuticalsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.